계정 가입
이미 존재한 계정
가입을 클릭하여 코인타임의 <a class="underline" href="#term-of-service">서비스 약관</a> 과 a class="underline" href="#privacy-policy">개인정보 보호 정책</a> . 에 동의함.
email 로 로그인
email 로 가입
사용자 이메일
수신함을 확인하세요
중의 링크를 통해 로그인 하세요
중의 링크를 통해 가입 하세요
Metacrine
company
About
Metacrine is a clinical-stage bio pharmaceutical company focused on building an innovative pipeline of best-in-class drugs.
- 11 - 50
Details
- Last Funding Type
- Series C
- Last Funding Money Raised
- $65M
- Industries
- Biotechnology,Health Care,Medical,Pharmaceutical
- Founded date
- Jan 1, 2015
- Number Of Employee
- 11 - 50
- Operating Status
- Active
Metacrine is a clinical-stage biopharmaceutical company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases. The most advanced program is focused on the farnesoid X receptor (FXR) an important drug target in multiple liver and GI diseases. Beyond the FXR program, a pipeline of novel drug candidates against other drug targets is being explored by taking advantage of internal drug discovery and development capabilities.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
3
$123M
Metacrine has raised a total of
$123M
in funding over 2 rounds. Their latest funding was raised on
Jun 6, 2018 from a Series C round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jun 6, 2018 | Series C | $65M | 2 | — | — | Detail |
| Dec 7, 2017 | Series B | $22M | 1 | — | — | Detail |
| Aug 5, 2015 | Series A | $36M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
2
Metacrine is funded by 2 investors.
ARCH Venture Partners
and Lilly Asia Ventures
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
ARCH Venture Partners
|
— | Series C |
Lilly Asia Ventures
|
— | Series C |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
